TapewireFind a company

person · Reporting owner

Barnes Alane P

Disclosed activity across 1 company

Tapewire entity
47066
SEC CIK
0001584348

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315Chief Legal OfficerMay 13, 2026May 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIOCRYST PHARMACEUTICALS INC

Report date May 13, 2026 · Filed May 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect400,703 Ending reported balance After 2026-05-13 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-05-13 · Exercise / conversion · Acquired 62,500 · Balance 463,203

F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Row 2 · 2026-05-13 · Sale · Disposed 62,500 · Balance 400,703

F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2027-12-20Direct0 Reported balance After 2026-05-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-05-13 · Exercise / conversion · Disposed 62,500 · Balance 0

F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F2: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F2: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 13, 2026 Filed May 15, 2026 20:08 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 62,500 $0.00 Strike: $5.04 $0.00
Disclosure

SEC source: 0000882796-26-000021 · form4.xml · derivative · entry 3

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 62,500 shares

Expires 2027-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F2 · derivative.exercise_date: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant.

Read SEC document
May 13, 2026 Filed May 15, 2026 20:08 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 62,500 $9.54 $596,250.00
Disclosure

SEC source: 0000882796-26-000021 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 400,703

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
May 13, 2026 Filed May 15, 2026 20:08 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 62,500 $5.04 $315,000.00
Disclosure

SEC source: 0000882796-26-000021 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 463,203

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:11 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 150,000 $0.00 Strike: $5.51 $0.00
Disclosure

SEC source: 0000882796-26-000015 · form4.xml · derivative · entry 3

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,000 shares

Expires 2027-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F3 · derivative.exercise_date: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:11 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 150,000 $9.15 $1,372,500.00
Disclosure

SEC source: 0000882796-26-000015 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 400,703

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.95 to $9.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:11 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 150,000 $5.51 $826,500.00
Disclosure

SEC source: 0000882796-26-000015 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 550,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
December 22, 2025 Filed Dec 23, 2025 21:11 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 21,773 $7.65 $166,563.45
Disclosure

SEC source: 0000882796-25-000043 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 398,751

F2 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
December 19, 2025 Filed Dec 23, 2025 21:11 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 16,902 $7.41 $125,243.82
Disclosure

SEC source: 0000882796-25-000043 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 420,524

F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:17 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 255,050 $0.00 Strike: $7.13 $0.00
Disclosure

SEC source: 0001171843-25-008037 · ownership.xml · derivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,050

Underlying: Common Stock · 255,050 shares

Expires 2035-12-17

F2 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:17 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 121,700 $0.00 $0.00
Disclosure

SEC source: 0001171843-25-008037 · ownership.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,426

F1 · shares: Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 15, 2025 Filed Dec 16, 2025 21:13 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 21,210 $7.65 $162,256.50
Disclosure

SEC source: 0000882796-25-000033 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 315,726

F2 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
December 12, 2025 Filed Dec 16, 2025 21:13 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 8,540 $7.57 $64,647.80
Disclosure

SEC source: 0000882796-25-000033 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 336,936

F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.

Read SEC document
December 03, 2025 Filed Dec 3, 2025 23:40 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 19,770 $7.65 $151,240.50
Disclosure

SEC source: 0000882796-25-000027 · form4.xml · nonDerivative · entry 4

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 345,476

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
December 02, 2025 Filed Dec 3, 2025 23:40 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 50,906 $7.21 $367,215.52
Disclosure

SEC source: 0000882796-25-000027 · form4.xml · nonDerivative · entry 3

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 365,246

F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.180 to $7.255. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
December 01, 2025 Filed Dec 3, 2025 23:40 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 91,004 $0.00 Strike: $3.22 $0.00
Disclosure

SEC source: 0000882796-25-000027 · form4.xml · derivative · entry 5

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 91,004 shares

Expires 2026-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F4 · derivative.exercise_date: The option grant became exercisable at the rate of 25.0% on each of the first, second, third, and fourth anniversaries of the date of grant.

Read SEC document
December 01, 2025 Filed Dec 3, 2025 23:40 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 91,004 $7.10 $646,510.62
Disclosure

SEC source: 0000882796-25-000027 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 416,152

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.015 to $7.190. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
December 01, 2025 Filed Dec 3, 2025 23:40 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 91,004 $3.22 $293,032.88
Disclosure

SEC source: 0000882796-25-000027 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 507,156

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
December 19, 2024 Filed Dec 23, 2024 21:05 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 250,100 $0.00 Strike: $7.39 $0.00
Disclosure

SEC source: 0001127602-24-029952 · form4.xml · derivative · entry 3

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,100

Underlying: Common Stock · 250,100 shares

Expires 2034-12-19

F3 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 19, 2024 Filed Dec 23, 2024 21:05 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 2,461 $7.39 $18,186.79
Disclosure

SEC source: 0001127602-24-029952 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 412,729

F2 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.

Read SEC document
December 19, 2024 Filed Dec 23, 2024 21:05 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 120,700 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-029952 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 415,190

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 14, 2024 Filed Dec 17, 2024 21:10 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 8,613 $7.53 $64,855.89
Disclosure

SEC source: 0001127602-24-029582 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,490

F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.

Read SEC document
May 13, 2024 Filed May 15, 2024 11:11 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 PurchaseCommon Stock 5,000 $5.53 $27,650.00
Disclosure

SEC source: 0001127602-24-015367 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,762

F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.36 to $5.64. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

Read SEC document
December 19, 2023 Filed Dec 20, 2023 21:33 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 2,482 $6.05 $15,016.10
Disclosure

SEC source: 0001127602-23-030177 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 293,539

F1 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.

Read SEC document
December 14, 2023 Filed Dec 18, 2023 21:34 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 158,500 $0.00 Strike: $6.43 $0.00
Disclosure

SEC source: 0001127602-23-029829 · form4.xml · derivative · entry 3

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,500

Underlying: Common Stock · 158,500 shares

Expires 2033-12-14

F3 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 14, 2023 Filed Dec 18, 2023 21:34 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 4,015 $6.43 $25,816.45
Disclosure

SEC source: 0001127602-23-029829 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 296,021

F2 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.

Read SEC document
December 14, 2023 Filed Dec 18, 2023 21:34 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 64,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-029829 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,036

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 19, 2022 Filed Dec 21, 2022 21:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 158,500 $0.00 Strike: $10.63 $0.00
Disclosure

SEC source: 0001127602-22-028084 · form4.xml · derivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,500

Underlying: Common Stock · 158,500 shares

Expires 2032-12-19

F2 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 19, 2022 Filed Dec 21, 2022 21:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 34,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-028084 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,770

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 15, 2022 Filed Dec 19, 2022 21:38 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 4,175 $10.88 $45,424.00
Disclosure

SEC source: 0001127602-22-027858 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 198,770

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2022 to cover tax withholding obligations in connection with the vesting of 13,750 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.33. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
December 14, 2021 Filed Dec 16, 2021 22:03 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 164,000 $0.00 Strike: $11.43 $0.00
Disclosure

SEC source: 0001127602-21-031126 · form4.xml · derivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,000

Underlying: Common Stock · 164,000 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 14, 2021 Filed Dec 16, 2021 22:03 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 75,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-031126 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,969

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 14, 2021 Filed Jan 13, 2022 21:36 UTC Amendment BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 55,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-001452 · form4a.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,969

F1 · shares: The number of restricted stock units awarded to the reporting person on December 14, 2021 was overstated in the original Form 4 due to an administrative error. This amendment corrects the error and reflects the corrected amount of restricted stock units awarded to the reporting person on such date.

Read SEC document
May 12, 2021 Filed May 13, 2021 20:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 35,852 $0.00 Strike: $4.73 $0.00
Disclosure

SEC source: 0001127602-21-016587 · form4.xml · derivative · entry 9

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,852 shares

Expires 2022-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The reporting person engaged in a non-market exercise and hold transaction with respect to these stock options and the underlying shares.

Read SEC document
May 12, 2021 Filed May 13, 2021 20:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 35,852 $4.73 $169,579.96
Disclosure

SEC source: 0001127602-21-016587 · form4.xml · nonDerivative · entry 5

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The reporting person engaged in a non-market exercise and hold transaction with respect to these stock options and the underlying shares.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 68,000 $0.00 Strike: $5.45 $0.00
Disclosure

SEC source: 0001127602-21-016587 · form4.xml · derivative · entry 8

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 68,000 shares

Expires 2023-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested upon the achievement of performance-based vesting criteria with respect to 17,000 shares on each of May 26, 2014, December 19, 2014, May 13, 2015 and December 3, 2020.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 33,132 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001127602-21-016587 · form4.xml · derivative · entry 7

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,132 shares

Expires 2023-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 1,648 $0.00 Strike: $4.73 $0.00
Disclosure

SEC source: 0001127602-21-016587 · form4.xml · derivative · entry 6

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,852

Underlying: Common Stock · 1,648 shares

Expires 2022-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 102,780 $12.04 $1,237,471.20
Disclosure

SEC source: 0001127602-21-016587 · form4.xml · nonDerivative · entry 4

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,275

F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.00 to $12.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 68,000 $5.45 $370,600.00
Disclosure

SEC source: 0001127602-21-016587 · form4.xml · nonDerivative · entry 3

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 33,132 $1.42 $47,047.44
Disclosure

SEC source: 0001127602-21-016587 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:43 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 1,648 $4.73 $7,795.04
Disclosure

SEC source: 0001127602-21-016587 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 15, 2020 Filed Dec 17, 2020 21:32 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 280,000 $0.00 Strike: $8.31 $0.00
Disclosure

SEC source: 0001127602-20-031791 · form4.xml · derivative · entry 1

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,000

Underlying: Common Stock · 280,000 shares

Expires 2030-12-15

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 11, 2020 Filed Dec 15, 2020 22:35 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 13,741 $0.00 Strike: $4.15 $0.00
Disclosure

SEC source: 0001127602-20-031406 · form4.xml · derivative · entry 3

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,741 shares

Expires 2021-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

Read SEC document
December 11, 2020 Filed Dec 15, 2020 22:35 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 13,741 $7.96 $109,378.36
Disclosure

SEC source: 0001127602-20-031406 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,061

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.95 to $7.97. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
December 11, 2020 Filed Dec 15, 2020 22:35 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 13,741 $4.15 $57,025.15
Disclosure

SEC source: 0001127602-20-031406 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,802

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

Read SEC document
December 04, 2020 Filed Dec 8, 2020 21:12 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 13,741 $0.00 Strike: $4.15 $0.00
Disclosure

SEC source: 0001127602-20-030837 · form4.xml · derivative · entry 3

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,741

Underlying: Common Stock · 13,741 shares

Expires 2021-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

Read SEC document
December 04, 2020 Filed Dec 8, 2020 21:12 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 13,741 $6.23 $85,606.43
Disclosure

SEC source: 0001127602-20-030837 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,061

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.22 to $6.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
December 04, 2020 Filed Dec 8, 2020 21:12 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 13,741 $4.15 $57,025.15
Disclosure

SEC source: 0001127602-20-030837 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,802

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

Read SEC document
December 03, 2020 Filed Dec 7, 2020 21:21 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 17,000 $0.00 Strike: $5.45 $0.00
Disclosure

SEC source: 0001127602-20-030700 · form4.xml · derivative · entry 1

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2023-08-08

F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020.

Read SEC document
February 21, 2020 Filed Feb 25, 2020 21:44 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 12,400 $0.00 Strike: $11.13 $0.00
Disclosure

SEC source: 0001127602-20-007677 · form4.xml · derivative · entry 1

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,400

Underlying: Common Stock · 12,400 shares

Expires 2024-12-22

F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.